Total Payments
$8,941
2024 Payments
$854.29
Companies
58
Transactions
500
Medicare Patients
3,179
Medicare Billing
$888,811
Payment Breakdown by Category
Food & Beverage$8,329 (93.2%)
Education$612.41 (6.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,329 | 489 | 93.2% |
| Education | $612.41 | 11 | 6.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,138 | 72 | $0 (2024) |
| Amgen Inc. | $961.01 | 53 | $0 (2023) |
| Janssen Biotech, Inc. | $818.86 | 46 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $713.12 | 32 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $709.87 | 50 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $670.36 | 35 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $394.90 | 19 | $0 (2024) |
| PFIZER INC. | $351.54 | 21 | $0 (2024) |
| Aveo Pharmaceuticals, Inc. | $221.31 | 2 | $0 (2024) |
| GENZYME CORPORATION | $219.07 | 15 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $854.29 | 37 | Aveo Pharmaceuticals, Inc. ($221.31) |
| 2023 | $467.94 | 25 | Amgen Inc. ($59.09) |
| 2022 | $1,389 | 82 | Merck Sharp & Dohme LLC ($287.88) |
| 2021 | $1,055 | 56 | Janssen Biotech, Inc. ($238.73) |
| 2020 | $894.20 | 47 | Amgen Inc. ($257.83) |
| 2019 | $1,414 | 77 | Pharmacyclics LLC, An AbbVie Company ($223.32) |
| 2018 | $1,710 | 110 | Merck Sharp & Dohme Corporation ($277.12) |
| 2017 | $1,156 | 66 | Novartis Pharmaceuticals Corporation ($232.33) |
All Payment Transactions
500 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Genentech USA, Inc. | Tecentriq (Biological), Tecentriq Hybreza | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: BioOncology | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.23 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/04/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $14.22 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.15 | General |
| Category: Hematology | ||||||
| 11/12/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $22.29 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: Oncology | ||||||
| 10/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: ONCOLOGY | ||||||
| 10/15/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 10/12/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $17.18 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $29.22 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.39 | General |
| 09/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.39 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $20.78 | General |
| Category: ONCOLOGY | ||||||
| 08/28/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $15.50 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/14/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $15.09 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 07/19/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $16.91 | General |
| Category: Oncology | ||||||
| 07/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.26 | General |
| Category: Oncology | ||||||
| 07/16/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: Oncology | ||||||
| 07/12/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Oncology | ||||||
| 07/09/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $25.07 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 197 | 417 | $38,824 | $14,025 |
| 2022 | 9 | 338 | 1,344 | $99,393 | $34,574 |
| 2021 | 30 | 1,030 | 32,828 | $613,246 | $225,027 |
| 2020 | 36 | 1,614 | 61,543 | $1.6M | $615,186 |
Total Patients
3,179
Total Services
96,132
Medicare Billing
$888,811
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 67 | 76 | $18,544 | $7,315 | 39.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 22 | 25 | $8,000 | $2,315 | 28.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $3,476 | $1,385 | 39.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 20 | 25 | $3,150 | $1,184 | 37.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 16 | $2,752 | $1,093 | 39.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 14 | 30 | $1,500 | $345.41 | 23.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 23 | 31 | $1,085 | $331.39 | 30.5% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 12 | 19 | $133.00 | $38.14 | 28.7% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 12 | 184 | $184.00 | $17.96 | 9.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 126 | 163 | $33,578 | $15,538 | 46.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 43 | 102 | $34,170 | $9,823 | 28.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $7,900 | $3,166 | 40.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 32 | 34 | $4,726 | $2,314 | 49.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 27 | 41 | $5,576 | $2,048 | 36.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 21 | 89 | $5,073 | $964.32 | 19.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 32 | 50 | $2,250 | $530.85 | 23.6% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2022 | 12 | 160 | $5,440 | $126.57 | 2.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 20 | 680 | $680.00 | $63.51 | 9.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 29 | 3,900 | $148,200 | $63,623 | 42.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 170 | 324 | $66,744 | $31,331 | 46.9% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2021 | 36 | 152 | $24,320 | $24,335 | 100.1% |
| 78815 | Nuclear medicine study with ct imaging skull base to mid-thigh | Office | 2021 | 20 | 20 | $62,560 | $21,402 | 34.2% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2021 | 22 | 21,750 | $65,250 | $19,454 | 29.8% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 53 | 182 | $60,970 | $19,240 | 31.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 177 | 225 | $31,275 | $13,628 | 43.6% |
About Dr. Steven Rhinehart, MD
Dr. Steven Rhinehart, MD is a Hematology & Oncology healthcare provider based in Fort Wayne, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1790787604.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Rhinehart, MD has received a total of $8,941 in payments from pharmaceutical and medical device companies, with $854.29 received in 2024. These payments were reported across 500 transactions from 58 companies. The most common payment nature is "Food and Beverage" ($8,329).
As a Medicare-enrolled provider, Rhinehart has provided services to 3,179 Medicare beneficiaries, totaling 96,132 services with total Medicare billing of $888,811. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Fort Wayne, IN
- Active Since 08/10/2005
- Last Updated 05/15/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1790787604
Products in Payments
- KEYTRUDA (Biological) $1,059
- Imbruvica (Drug) $386.93
- DARZALEX (Biological) $364.85
- IMBRUVICA (Drug) $332.40
- ELIQUIS (Drug) $316.42
- OPDIVO (Biological) $310.15
- DARZALEX (Drug) $288.81
- FOTIVDA (Drug) $221.31
- Kyprolis (Biological) $214.47
- TAGRISSO (Drug) $214.32
- FOUNDATIONONE (Device) $197.84
- Lenvima (Drug) $193.02
- Kyprolis (Drug) $177.77
- IBRANCE (Drug) $177.69
- AFINITOR (Drug) $173.34
- Doptelet (Drug) $165.84
- JEVTANA (Drug) $145.07
- KISQALI (Drug) $130.05
- JAKAFI (Drug) $119.10
- CALQUENCE (Drug) $111.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fort Wayne
Sunil Babu, M.d, M.D
Hematology & Oncology — Payments: $257,612
Hematology & Oncology $257,612
Dolly Quispe Leveau, M.d, M.D
Hematology & Oncology — Payments: $73,162
Hematology & Oncology $73,162
Jeffrey Letzer, Do, DO
Hematology & Oncology — Payments: $43,943
Hematology & Oncology $43,943
Dr. Robert Manges, Md, MD
Hematology & Oncology — Payments: $42,660
Hematology & Oncology $42,660
Farrukh Adhami, Md, MD
Hematology & Oncology — Payments: $35,244
Hematology & Oncology $35,244
Dr. Murugavel Muthusamy, M.d, M.D
Hematology & Oncology — Payments: $23,326
Hematology & Oncology $23,326